Valuation : ORIC Pharmaceuticals, Inc.

Market Cap 1.37B 1.18B 1.11B 1.01B 1.91B 131B 1.91B 13.15B 5.13B 66.21B 5.15B 5.04B 220B P/E 2026 *
-8.72x
P/E 2027 * -8.04x
Enterprise Value 1.37B 1.18B 1.11B 1.01B 1.91B 131B 1.91B 13.15B 5.13B 66.21B 5.15B 5.04B 220B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
1 day-3.64%
1 week-6.76%
Current month+19.60%
1 month+11.17%
3 months+56.69%
6 months-1.56%
Current year+61.86%
1 week 13.2
Extreme 13.2
14.52
1 month 10.45
Extreme 10.45
14.68
Current year 7.23
Extreme 7.23
14.68
1 year 7.23
Extreme 7.23
14.93
3 years 3.9
Extreme 3.8951
16.65
5 years 2.36
Extreme 2.36
26.7
10 years 2.36
Extreme 2.36
40.81
Manager TitleAgeSince
Chief Executive Officer 47 07/05/2018
Director of Finance/CFO 52 01/09/2019
Chief Tech/Sci/R&D Officer - 18/08/2025
Director TitleAgeSince
Chairman 68 07/03/2018
Director/Board Member 47 07/05/2018
Director/Board Member 62 01/02/2020
Date Insider Type Main position Quantity % Market Cap.
24/7/26 Fiscal year

Founder

20,100 0.0194%
6/7/26 Sell

Founder

-300 0.0003%
24/2/26 Fiscal year

Chief Financial Officer

156,000 0.1602%
Change 5-day change 1-year change 3-year change Capi.($)
-3.64%-6.76%+32.00%+48.43% 1.37B
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -2.18%-2.41%+56.58%+178.01% 28.33B
Weighted average by Cap. -1.94%-1.53%+57.03%+152.32%

Financials

2026 *2027 *
Net sales - -
Net income -166M -143M -134M -122M -230M -15.83B -231M -1.59B -619M -7.99B -622M -608M -26.5B -197M -170M -159M -145M -274M -18.82B -274M -1.89B -736M -9.5B -739M -723M -31.49B
Net Debt - -
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
111
Date Price Change Volume
28/08/26 USD 13.24 -3.64% 765,429
27/08/26 USD 13.74 -1.22% 1,060,961
26/08/26 USD 13.91 +0.58% 1,123,808
25/08/26 USD 13.83 +2.75% 1,168,791
24/08/26 USD 13.46 -5.21% 1,110,088
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
13.24USD
Average target price
20.67USD
Spread / Average Target
+56.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ORIC Stock